GlassScriptPhysician profile
Jamie Prince
NPI 1306402359
$3,900.91
in general payments reported to CMS, 2019-2025
17 companies · $566 in 2025
The $566 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $270 · 2021: $512 · 2022: $869 · 2023: $1,009 · 2024: $674 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,220 · Travel and Lodging: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,219.58 |
| Travel and Lodging | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,612.36 | 2020-2023 | Tecnis Iol, Tecnis Simplicity |
| Alcon Vision LLC | $411.84 | 2023-2024 | Constellation, Hydrus Microstent |
| Glaukos Corporation | $346.71 | 2022-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb Americas INC. | $313.12 | 2022-2023 | Stellaris |
| Astellas Pharma US INC | $181.32 | 2024-2025 | Izervay |
| Nova Eye, INC. | $147.09 | 2025 | |
| Sight Sciences, INC. | $146.20 | 2021-2022 | |
| Alimera Sciences, INC. | $131.21 | 2024 | Yutiq, Iluvien |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.10 | 2025 | |
| Oculus Surgical INC. | $104.20 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $101.55 | 2025 | Eylea Hd |
| Dutch Ophthalmic, USA | $92.02 | 2024 | Tissueblue, Eva, Combined Machine |
| Tarsus Pharmaceuticals, INC. | $76.58 | 2024 | |
| Carl Zeiss Meditec USA, INC. | $51.06 | 2023 | Quatera 700 |
| Carl Zeiss Meditec Cataract Technology INC. | $32.30 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $24.72 | 2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $17.53 | 2025 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Prince listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.